Prostate cancer

#Breast cancer #DNA mutations #Drug therapy #Gene therapy #Prostate cancer #sympos

This week in Drug Discovery (13 – 17 October)

News round-up for 13 – 17 October by Bruno Quinney, Content Team at DDW.  This week’s top story comes from new research showing drug therapies could prevent hereditary diseases. Elsewhere, there have been major developments in cancer research and gene therapy could help combat hearing loss. … Read More

#News

Prostate cancer cells
#Cancer research #Prostate cancer

Major study into prostate cancer offers hope for new treatments 

New research uncovering a vulnerability in prostate cancer cells could provide ways to improve treatments for prostate cancer.  A major international study, led by scientists from Flinders University in Australia and South China University of Technology, revealed that two enzymes, PDIA1 and PDIA5, play a… Read More

#News

Doctor showing a model of the prostate
#Bayer #Health Canada #Oncology #Prostate cancer

Health Canada extends approval of Bayer’s darolutamide

Health Canada has granted marketing authorisation for Bayer’s oral androgen receptor inhibitor (ARi) Nubeqa (darolutamide) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).   This authorisation is based on results from the Phase III ARANOTE trial, which showed that darolutamide plus ADT reduced the risk of radiological progression… Read More

#News #Regulatory

Prostate cancer cells
#Archeus Technologies #FDA #Oncology #Phase I trial #Prostate cancer #Radiopharmaceuticals

FDA clears radiopharmaceutical for prostate cancer

The US Food and Drug Administration (FDA) has cleared Archeus Technologies’ Investigational New Drug (IND) application for ART-101, a novel receptor-based targeting small molecule for the imaging and treatment of prostate cancer.   This clearance enables the company to initiate a Phase I clinical trial in men with metastatic castration-resistant prostate… Read More

#Cancer Research #News #Regulatory

#Mergers and acquisitions #Oncology #Prostate cancer #Radiopharmaceuticals #RayzeBio

RayzeBio buys prostate cancer radiopharmaceutical for $1.35bn

Philochem and RayzeBio, a subsidiary of Bristol-Myers Squibb, have announced a definitive agreement under which RayzeBio will purchase the exclusive worldwide rights to prostate cancer therapeutic OncoACP3.  OncoACP3 is a small molecule ligand with high affinity and specificity for Acid Phosphatase 3 (ACP3), a novel target in prostate cancer.   The… Read More

#Business & Investment #News

#Cancer research #Parabilis Medicines #Prostate cancer #Toxicology

Cracking the ERG code in prostate cancer

Parabilis has achieved the first pharmacological proof-of-concept for degrading the long-considered ‘undruggable’ transcription factor ERG in prostate cancer. DDW’s Megan Thomas speaks with Dr Jonathan Hurov, Executive Vice President, Discovery Biology at Parabilis Medicines, about the milestone. MT: ERG has been considered ‘undruggable’ for decades. Why is this?   JH: ERG… Read More

#Cancer Research #Exclusive Content

Cancer research in laboratory
#Investment #Oncology #Prostate cancer #University of Queensland

$1.25 million support for advanced prostate cancer drug

A $1.25 million investment is driving the development of a new treatment for advanced and therapy-resistant prostate cancer at The University of Queensland.  Based on research by Professor Greg Monteith from UQ’s School of Pharmacy and Pharmaceutical Sciences, the drug (QED-203) is being developed by the Queensland… Read More

#Cancer Research #Editor's Choice #News

Prostate cancer cells
#Bladder cancer #Immunotherapy #Oncology #Prostate cancer #UCLA

Immunotherapy with chemotherapy effective for rare cancers

New research has found that combining immunotherapy with chemotherapy is safe and effective for people with advanced small cell cancers in the bladder and prostate. A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, an immunotherapy drug, with… Read More

#Cancer Research #Editor's Choice #News

Prostate cancer cells
#Australia #Flinders University #Oncology #Prostate cancer #Protein inhibitor

Potential breakthrough in treating prostate cancer

Researchers from Flinders University and University of South Australia have unveiled a promising new strategy that could be used to treat the most aggressive forms of prostate cancer. This study, published in British Journal of Cancer, explores the role of a novel drug, CDKI-73, to tackle… Read More

#Cancer Research #Editor's Choice #News

#FDA #Oncology #Prostate cancer #Syncromune

FDA grants Fast Track designation to prostate cancer treatment

Biopharmaceutical company Syncromune has had its lead-candidate for the treatment of metastatic castrate-resistant prostate cancer (mCRPC) granted Fast Track designation by the FDA. Syncromune’s SYNC-T SV-102 therapy is a personalised treatment that comprises of an in situ vaccine via partial oncolysis of a tumour followed by intratumoral infusion of the SV-102 fixed-dose… Read More

#Cancer Research #News #Regulatory

Cancer research in lab
#Antigen #Immunology #Oncology #Prostate cancer #University of California San Francisco

Study reveals insights into antigen reactivity in prostate cancer

Researchers from the University of California, San Francisco (UCSF) shared new data on foundational prostate cancer antigen research at the 2024 Annual Meeting of the American Association of Immunologists (AAI) in Chicago. Prostate cancer’s low mutation burden has resulted in very few druggable neoantigens –… Read More

#Cancer Research #News

Prostate cancer cells
#mRNA #Nutcracker Therapeutics #Oncology #Prostate cancer #T cell activation

mRNA prostate cancer drug successfully engaged CD3 T cells

Nutcracker Therapeutics’ prostate cancer mRNA drug candidate NTX-470 successfully engaged CD3 T cells, while retaining low bystander activity and reduced off-tumour binding, according to data presented at the 2024 AACR Annual Meeting. There are limited treatment options for the 10-20% of prostate cancer patients who develop… Read More

#Cancer Research #News

#Arvinas #License agreement #Novartis #Prostate cancer #PROTAC #Protein degradation

Novartis buys Arvinas’ prostate cancer protein degrader for $150m

Biotechnology company Arvinas has entered into an exclusive strategic license agreement with Novartis for ARV-766, Arvinas’ second generation PROTAC androgen receptor (AR) degrader for patients with prostate cancer. The transaction also includes an asset purchase agreement for the sale of Arvinas’ preclinical AR-V7 programme, a splice variant of the AR. Read More

#Business & Investment #News

Prostate cancer cells
#Oncology #Phase II trial #Promontory Therapeutics #Prostate cancer

Prostate cancer drug shows ‘promising’ mechanism of action

Pharmaceutical company Promontory Therapeutics has completed enrolment of its Phase II clinical trial of lead therapeutic candidate, PT-112, in patients with late-line metastatic castration-resistant prostate cancer (mCRPC). The study is evaluating PT-112 in patients who have been treated with at least three prior life-prolonging therapies… Read More

#Cancer Research #News